Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTMD NASDAQ:EXOZ NYSE:JATT NASDAQ:KZIA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.14-3.4%$1.81$1.27▼$4.75$84.84M1.71222,376 shs68,774 shsEXOZeXoZymes$9.91+1.1%$8.96$7.08▼$18.40$84.38M2.854,132 shs440 shsJATTJATT Acquisition$10.79+2.6%$7.48$9.99▼$11.31$84.16MN/A13,653 shs1,642 shsKZIANovogen$13.96-1.0%$9.49$3.22▼$17.40$23.03M2.22223,129 shs13,121 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+1.38%+0.91%+38.99%0.00%-44.61%EXOZeXoZymes-2.34%+0.51%-16.24%-5.50%-24.67%JATTJATT Acquisition-0.04%+0.01%+90.28%+71.47%+788.51%KZIANovogen-2.35%+5.30%+59.86%+158.24%+279.03%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTMDbiote$2.14-3.4%$1.81$1.27▼$4.75$84.84M1.71222,376 shs68,774 shsEXOZeXoZymes$9.91+1.1%$8.96$7.08▼$18.40$84.38M2.854,132 shs440 shsJATTJATT Acquisition$10.79+2.6%$7.48$9.99▼$11.31$84.16MN/A13,653 shs1,642 shsKZIANovogen$13.96-1.0%$9.49$3.22▼$17.40$23.03M2.22223,129 shs13,121 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTMDbiote+1.38%+0.91%+38.99%0.00%-44.61%EXOZeXoZymes-2.34%+0.51%-16.24%-5.50%-24.67%JATTJATT Acquisition-0.04%+0.01%+90.28%+71.47%+788.51%KZIANovogen-2.35%+5.30%+59.86%+158.24%+279.03%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTMDbiote 2.25Hold$2.7528.81% UpsideEXOZeXoZymes 1.00SellN/AN/AJATTJATT Acquisition 0.00N/AN/AN/AKZIANovogen 2.50Moderate Buy$21.0050.48% UpsideCurrent Analyst Ratings BreakdownLatest KZIA, EXOZ, JATT, and BTMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026KZIANovogen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026BTMDbiote Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $4.004/15/2026KZIANovogen LaidlawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$25.003/12/2026BTMDbiote National Bank FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$2.503/12/2026BTMDbiote TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$3.00 ➝ $2.503/12/2026BTMDbiote B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$3.00 ➝ $2.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTMDbiote$192.22M0.44$0.57 per share3.76($1.40) per share-1.53EXOZeXoZymes$70K1,200.04N/AN/A$0.40 per share24.77JATTJATT AcquisitionN/AN/A$0.40 per share27.08($0.53) per shareN/AKZIANovogen$30K767.53N/AN/A($5.34) per share-2.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTMDbiote$27.05M$0.444.886.28N/A8.29%-24.04%14.46%N/AEXOZeXoZymes-$9.16M-$1.08N/AN/AN/AN/A-147.18%-104.98%N/AJATTJATT Acquisition$6.85MN/AN/AN/AN/AN/A-49.58%2.84%N/AKZIANovogen-$13.41MN/AN/AN/AN/AN/AN/AN/AN/ALatest KZIA, EXOZ, JATT, and BTMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2026Q1 2026BTMDbiote$0.09$0.06-$0.03$0.06$46.02 million$44.94 million3/30/2026Q4 2025EXOZeXoZymesN/A-$0.31N/A-$0.31N/AN/A3/19/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/AN/A3/11/2026Q4 2025BTMDbiote$0.05$0.06+$0.01$0.06$45.79 million$46.41 million2/14/2026Q2 2026KZIANovogenN/A-$1.34N/A-$1.34N/A$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBTMDbioteN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTMDbioteN/A1.220.79EXOZeXoZymes0.022.512.51JATTJATT AcquisitionN/A0.150.15KZIANovogenN/A2.87N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTMDbiote21.68%EXOZeXoZymesN/AJATTJATT Acquisition47.97%KZIANovogen30.89%Insider OwnershipCompanyInsider OwnershipBTMDbiote32.40%EXOZeXoZymes72.41%JATTJATT Acquisition20.00%KZIANovogen1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTMDbiote19439.55 million26.74 millionNot OptionableEXOZeXoZymes298.48 million2.34 millionN/AJATTJATT Acquisition37.80 million13.80 millionNot OptionableKZIANovogen121.65 million1.64 millionNo DataKZIA, EXOZ, JATT, and BTMD HeadlinesRecent News About These CompaniesKazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major CatalystApril 30, 2026 | seekingalpha.comKazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology PlatformApril 15, 2026 | prnewswire.comKazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development PlatformApril 13, 2026 | prnewswire.comKazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)January 30, 2026 | prnewswire.comKazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast CancerJanuary 27, 2026 | prnewswire.comKazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-EndJanuary 8, 2026 | prnewswire.comKazia Therapeutics Regains Full Nasdaq Listing ComplianceDecember 22, 2025 | prnewswire.comKazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+December 10, 2025 | prnewswire.comKazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity SecuritiesDecember 2, 2025 | prnewswire.comKazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory StrategyNovember 18, 2025 | prnewswire.comKazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunnerOctober 27, 2025 | prnewswire.comKazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader ProgramOctober 7, 2025 | prnewswire.comKazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy RegimenOctober 2, 2025 | prnewswire.comKazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMGOctober 1, 2025 | prnewswire.comKazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib MonotherapySeptember 11, 2025 | prnewswire.comKazia Therapeutics Announces $2 Million Private Placement at Premium to MarketAugust 1, 2025 | prnewswire.comKazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b TrialJuly 9, 2025 | prnewswire.comKazia Therapeutics Shares Jump After Data Shows Lead Asset Could Treat Breast CancerJune 11, 2025 | marketwatch.comKazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer (TNBC)June 11, 2025 | prnewswire.comKazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast CancerJune 5, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKZIA, EXOZ, JATT, and BTMD Company Descriptionsbiote NASDAQ:BTMD$2.13 -0.08 (-3.39%) As of 11:06 AM Eastern This is a fair market value price provided by Massive. Learn more.biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.eXoZymes NASDAQ:EXOZ$9.91 +0.11 (+1.08%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.JATT Acquisition NYSE:JATT$10.79 +0.27 (+2.57%) As of 10:28 AM Eastern This is a fair market value price provided by Massive. Learn more.JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Novogen NASDAQ:KZIA$13.96 -0.15 (-1.03%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
